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The spectrum of primary immunodeﬁciencies
at a tertiary care hospital in Pakistan
Sonia Qureshia, Fatima Mira, Samina Junejob, Khalid Saleemc, Samreen Zaidid, Abdullah B. Naveede,
Khalil Ahmada and Farah Naz Qamara*

ABSTRACT
Background: Primary Immunodeﬁciency Disorders (PIDs) are well-known disorders in the West.
but the recognition and diagnosis of these disorders is challenging in developing countries. We
present the spectrum of PIDs seen at a tertiary care center in Pakistan, identiﬁed using clinical case
deﬁnitions and molecular methods.
Methods: A retrospective chart review of children suspected to have PID was conducted at the
Aga Khan University Hospital (AKUH) Karachi, Pakistan from 2010 to 2016. Data on demographics,
clinical features, family history of consanguinity, sibling death, details of laboratory workup done
for PID and molecular tests targeted panel next generation sequencing (NGS) or whole exome
sequencing (WES) performed at the Geha laboratory at Boston Children’s Hospital, USA was
collected. The study was exempted from the Ethical Review Committee of AKUH.

Results: A total of 43 children visited the hospital with suspected PID during the study period.
Genetic testing was performed in 31/43 (72.1%) children. A conﬁrmed diagnosis of PID was
established in 20/43 (46.5%) children. A pathogenic gene variant was identiﬁed in 17(85%) of the
20 conﬁrmed cases (Table 1). Twelve (60%) of the conﬁrmed cases of PID were male. The most
common presenting symptom was recurrent diarrhea 11/20 (55%). The mean (S.D) age of the
cases at the time of diagnosis was 4.2 (4.1) years. Chronic granulomatous disease (CGD) was the
most common 6/20 (30%) disorder, followed by severe combined immunodeﬁciency (SCID) 3/20
(15%), leukocyte adhesion deﬁciency (LAD) 3/20 (15%), agammaglobulinemia/hypogammaglobulinemia 3/20 (15%), and Hermansky-Pudlak Syndrome (HPS) 2/20 (10%). Wiskott-Aldrich
Syndrome, Immunodeﬁciency Centromeric Instability and Facial Anomalies Syndrome (ICF 2),
Trichohepatoenteric syndrome (TRES), and C3 deﬁciency were each diagnosed once {1/20 (4.3%)
each} (Table 1). Of these 20 conﬁrmed cases, almost all 19/20 (95%) had a family history of
consanguinity. Sibling death was reported in 5/20 (25%) of these cases. Five out of the 20 (25%)
children died over the 7-year period for various reasons.

Conclusion: PIDs are not uncommon in Pakistan; their diagnosis may be missed or delayed due to the
overlapping of clinical features of PID with other diseases and a lack of diagnostic facilities. There is a
need to build capacity for early recognition and diagnosis of PIDs to decrease morbidity and mortality.

Keywords: Children, Primary immunodeﬁciency disorders, Chronic granulomatous disease,
Consanguineous marriages
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INTRODUCTION
Primary immunodeﬁciency disorders (PIDs) are
a heterogeneous group of genetic disorders
characterized by an impaired ability of the immune
system to produce a normal immune response.
This is due to inherited defects in either cellular or
humoral immunity, which results in a spectrum of
issues such as recurrent infections, allergies,
autoimmunity, and malignancies.1,2 In neonates,
PIDs often present with severe infections leading
to death; whereas in adolescents these infections
are less severe albeit recurrent. Diagnosing PIDs
is challenging because of the variability in clinical
presentation and limited availability of diagnostic
tests, particularly in low middle-income countries
(LMIC). When diagnostic tests are available, their
cost often becomes a limiting factor. Advances in
molecular diagnostic techniques and the identiﬁcation of known gene defects have helped to
facilitate the diagnosis of patients with PIDs.3 The
true global prevalence and distribution of PIDs
remain unclear. The prevalence statistics available
from nationwide registries are mostly derived
from limited areas of the world. The data
obtained
from
these
registries
often
underestimate the true prevalence, because not
all cases are reported to these registries, and due
to ambiguity in what constitutes a PID case, some
cases are missed. These issues are compounded
in developing countries because of the lack of
physician training in identiﬁcation of these
disorders and the limited access to diagnostics in
these countries. Recent studies have shown that
PIDs are more common than previously thought,
and that around 1% of the population may have
an underlying PID.4 The burden of PID varies by
region, being highest in the United States of
America (USA), followed by Europe, Latin
America, Middle East, Asia, and ﬁnally Africa.4
This frequency may be biased by the availability
of resources for diagnosis of these disorders.
Most PIDs are autosomal recessive, which makes
it safe to assume that the incidence of PIDs is
greater in regions having higher rates of consanguinity. However, limited studies have been carried out in such regions and hence the burden and
type of PIDs in such areas is relatively unknown.

Consanguineous marriages are common in
developing Asian countries ranging between 20
and 70% of all marriages, and Pakistan is no
different, with about 70% of the marriages being
consanguineous.5–7 The data on PIDs in Pakistan is
currently conﬁned to a few case reports, case
series, and editorials; there are no detailed
reports on the spectrum of PIDs seen in the
country.8–11
Diagnosing and treating PIDs is a challenge in
Pakistan. Patients often die before the disorder is
recognized by a physician, leading to a delay in
diagnosis or death of the child. Families are often
referred to tertiary care centers following the death
of a sibling or for admission for life-threatening
infections. Even in large tertiary care centers with
well-equipped laboratories, there are limited
diagnostic facilities available for conﬁrming PIDs.
Even when these are available, the diagnostic tests
are expensive and beyond the reach of most
families as the health care system of Pakistan relies
on out-of-pocket payments for health expenditures. Once the diagnosis of PID is conﬁrmed,
supportive therapies like antibiotic and antifungal
prophylaxis, intravenous (I/V), or subcutaneous (S/
C) immunoglobulin therapy, depending on the
underlying disorder, are offered. Intravenous
immunoglobulin (IVIG) is the standard therapy for
most humoral deﬁciencies, but it is expensive and
beyond the reach of most patients in low middle
income countries (LMICs). S/C immunoglobulins
provide ease of administration, but their availability is limited in LMICs. Bone marrow transplant is
available in certain settings but has its limitations in
countries like Pakistan where no donor registries
are available, and the cost of the transplant
coupled with the risk of infections in the posttransplant period make this option challenging to
pursue. Gene therapy is another promising albeit
costly treatment option undergoing experimentation and is now considered an option for the
treatment of multiple non-life-threatening disorders (ie, immunological disorders and systemic
protein deﬁciency). This study aims to report the
spectrum of PID cases observed at a tertiary care
center in Pakistan, with a focus on the molecular
diagnosis in this patient population over the last 7
years.
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MATERIALS AND METHODS
The Aga Khan University Hospital (AKUH) is a
700 bed, not-for-proﬁt tertiary care hospital in
Karachi, Pakistan. The hospital receives referrals
from all over the country. A retrospective chart
review of children suspected to have PID was
conducted at the AKUH, Pakistan from 2010 to
2016. Data on demographics, clinical features, age
at onset of symptoms, age at presentation, history
of recurrent infections, skin allergies, family history
of consanguinity, sibling death, details related to
laboratory workup done for PID (complete blood
count, serum immunoglobulin levels, nitrotetrazolium
blue
test
(NBT),
dihydrorhodamine(DHR) and ﬂow cytometric analysis)
were collected. Molecular tests targeted panel
next generation sequencing (NGS) or whole
exome sequencing (WES) were performed at Geha
laboratory at Boston Children’s Hospital, USA.
Targeted panel NGS was performed using the PID
v2 panel and Ion TorrentÔ S5 sequencer (ThermoFisher), with an average coverage of 328x.
Variant annotation was performed with VarSeqÔ
software (Golden Helix). Whole exome sequencing
(WES) was performed using a previously described
pipeline with an average on-target coverage of
80.12 The cost of shipping and molecular testing
was covered by a philanthropic grant from the
Perkins Fund. Data were analyzed using IBM
SPSS Statistics v. 20.0. Mean  S.D is reported for
quantitative variable like age at diagnosis, delay
in diagnosis (days), etc. Frequency and
percentages are reported for categorical
variables such as gender, type of PID, clinical
features, history of sibling death, consanguinity in
family, mortality, etc.

RESULTS
A total of 43 children visited the hospital with a
suspected PID during the study period. Among
them, genetic testing was performed in 31/43
(72.1%) children. A conﬁrmed diagnosis was
established in 20/43 (46.5%) children. A pathogenic gene variant was identiﬁed in 17 (85%) of the
20 conﬁrmed cases (Table 1). Of the remaining 23
patients, samples for 9 patients were not sent for
molecular testing, 7 had no known genetic
mutation for PID (Table 2), no pathogenic genetic
variant was identiﬁed in 2 patients, 2 died before
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a ﬁnal diagnosis could be established, 2 were
lost to follow-up, and 1 had normal sequencing
results (Fig. 1). Twelve (60%) of the 20 conﬁrmed
children with PID were male. The mean (S.D)
age at the time of diagnosis was 4.2 (4.1) years.
The mean (S.D) delay in diagnosis was
1333  1420 days. The most common presenting
symptom was recurrent diarrhea 11/20 (55%)
followed by recurrent pneumonia 8/20 (40%),
oral thrush 7/20 (35%), skin rashes and abscesses
6/20 (30%), osteomyelitis 1/20 (5%), and
meningitis 1/20 (5%). Chronic granulomatous
disease (CGD) was the most common 6/20 (30%)
disorder,
followed
by
severe
combined
immunodeﬁciency (SCID) 3/20 (15%), leukocyte
adhesion
deﬁciency
(LAD)
3/20
(15%),
agammaglobulinemia/hypogammaglobulinemia
3/20 (15%), and Hermansky-Pudlak Syndrome
(HPS) 2/20 (10%). Wiskott-Aldrich Syndrome, Immunodeﬁciency Centromeric Instability and Facial
Anomalies Syndrome (ICF 2), Trichohepatoenteric
syndrome (TRES), and C3 deﬁciency were each
diagnosed once {1/20 (4.3%) each} (Table 1). Of
these 20 conﬁrmed cases, almost all 19/20 (95%)
had a family history of consanguinity. Sibling
death was reported in 5/20 (25%) of these cases.
Five out of 20 (25%) children died due to various
reasons. A pathogen (Pneumocystis jiroveci) was
identiﬁed in only 1 of the 5 deceased patients.
Among the deceased children, 2 developed
acute respiratory distress syndrome (ARDS), 2
died of sepsis, and 1 had plastic bronchitis.

DISCUSSION
In this case series, 85% of the children were able
to get a molecular diagnosis through the support
of Boston Children’s Hospital. CGD was the commonest disorder observed. This is consistent with
data reported from other Asian countries in which
phagocytic defects were the most common type of
PIDs ranging from 29% to 60%.13–15 Almost all
cases in this study had a family history of
consanguinity. Death of siblings was seen in 25%
of the cases. Out of the children who died during
the study period, 80% of them were diagnosed
after they had died.
Due to a lack of facilities, diagnosing PIDs continues to be a challenge in developing countries.
Partnering with international organizations is

Consan
guinity

a

Special
Investigations
(Normal range)

Mutated
Gene

Final Diag
nosis

Age at
onset of
sym
ptom

Age at
diag
nosis

Out
come

Phagocyte Defects (n ¼ 9)
1

11 mo/M

Recurrent abscesses
and osteomyelitis

Yes

Yes (18 mo old
brother & 16 days
old brother with
no apparent
cause)

NBT: Negative
DHR: Positive
Immunoglobulins
IgG:15.2 (6.5–16)
IgA: 3.68 (0.4–3.5)
IgM:1.15 (0.5–3.0)
IgE: not done
Flow cytometry
Not done
HIV-serology: not done

Gene
NCF1
Loss of
coverage
Exon 2 could
not be
ampliﬁed,
suggesting a
deletion that
includes this
exon

AR CGD

2

3.3 yr/M

Recurrent abscesses,
lymphad enopathy

No

Yes (9 mo old
brother due to
pneumonia)

NBT: Negative
DHR: Not done
Immunoglobulins
IgG:23.1 (5.7–17.1)
IgA: 3.58 (0.47–2.5)
IgM:2.38 (0.64–2.7)
IgE: not done
Flow Cytometry
CD3: 5203 (1500–2900)
CD4: 2328 (1000–2100)
CD8: 1999 (700–1100)
CD19: 2407(500–1200)
CD 56: 556 (300–600)
HIV-serology:Negative

Gene
CYBB
Zygosity
Homozygous
Genomic
coordinate
c.1222G > A
Amino acid
Change
p.Gly408Arg

X-linked CGD

3

3 mo/M

Recurrent diarrhea,
perianal abscess, skin
rash

Yes

No

NBT: Negative
DHR: Not done
Immunoglobulins
IgA: 0.2 (0.09–1.07)
Others: not done
Flow Cytometry
CD3: 1652(1800–3300)
CD4: 1224 (900–2300)
CD8: 237 (700–1500)
CD19: 839(700–1700)
CD 56: not done
HIV status: not checked

Gene
NCF1
Zygosity
Homozygous
Genomic
coordinate
c.294_
295insA
Amino acid
change
p.Gly99fs

AR CGD

4

1.3 yr/F

Recurrent
diarrhea, cow
milk protein
allergy

Yes

Yes (1.5 years old
sister due to septic
shock & had
similar complaints,
no workup done
for PID)

NBT: Absent activity
DHR: Not done
Immunoglobulins
IgG:13.4 (6.5–16.0)
IgA:2.49 (0.4–3.5)
IgM:1.14 (0.5–3.0)
IgE: 1336 (0.4–351.6)
Flow cytometry
CD3: 5030 (1900–2900)
CD4: 3617 (1000–1800)
CD8: 1388 (700–1200)
CD19: 5073(600–1400)
CD56:1279 (300–600)
HIV status: not checked

Gene
NCF2
Zygosity
Homozygous
Genomic
coordinate
Chr1:
183532647
Loss of
coverage:
1098_
1099delTC
¼ p.Gln367fs
(Frameshift
deletion)

AR CGD

Birth

Birth

6 yr

Alive

9 mo

8 yr 9 mo

Alive

2 mo

2 yr
9 mo

Alive

2 yr

Alive
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Clinical
Features

4

S.No

Age/
Sex

Sibling
Death
(Age/
Cause of
death)

3 yr/M

Recurrent
pneumonias, oral
thrush, perianal
abscess
lymphadenopathy

Yes

No

NBT: Normal
DHR: Not done
Immunoglobulins
IgG: 7.62 (.05–14.0)
IgA:1.56((0.18–1.7))
IgM: 1.20(0.63–2.9)
IgE: >2000(0.4–351.6)
Flow cytometry
CD3: 6124(1500–2900)
CD4: 3355(1000–2100)
CD8: 2539(700–1100)
CD19:1830(500–1200)
CD56:not done
HIV serology: Negative

Gene
NCF1
Zygosity
Homozygous
Genomic
coordinate
Chr7:
74191664
Amino acid
change
p.Arg42Trp

AR CGD

2 yr

4 yr
5 mo

Alive

6.

7 yr/M

Recurrent pneumonia

Yes

No

NBT: Not done
DHR: Positive
Immunoglobulins
Not done
Flow cytometry
Not done
HIV status: not checked

Not done

CGD

9 mo

7 yr

Alive

7.

3.5 mo/F

Delayed shedding of
umbilical cord,
recurrent oral thrush,
skin rash,

Yes

No

Immunoglobulins
Not done
Flow cytometry
Not done
HIV status: not checked

Gene
FERMT3
Zygosity
Homozygous
Loss of
coverage
(Kindlin-3)
c.126_
126delC ¼
p.Ile42fs
(Frameshift
deletion)

LAD3

2 mo

1yr 4 mo

Alive

8.

7 mo/F

Delayed shedding of
umbilical cord,
recurrent diarrhea,
skin rash

Yes

No

Immunoglobulins
IgG:4.02
(6.5–16)
IgM:1.36
(0.5–3.0)
IgA: 0.36 (0.4–3.5)
IgE: 31.0 (1.4–52.3)
Flow Cytometry
CD3: 3987 (2800–3500)
CD4: 3122 (1700–2400)
CD8: 784 (800–1100)
CD 56: 444 j(300–800)
CD19: 2168 (1000–1700)
HIV status: not checked

Gene
ITGB2
Zygosity:
Homozygous
Genomic
coordinate
(GRCh37/
hg19): c.134G
>A
Amino acid
change
p.Trp45Ter
(Nonsense)

LAD1

12 days

5 mo

Alive

9.

4 mo/M

Delayed shedding of
umbilical cord and
umbilical abscess

Yes

No

c

Flow cytometry for LAD
markers:
CD11C deﬁciency

Not done

LAD2

3 mo

Alive

Yes

No

Immunoglobulins
IgG: <0.7 (6.5–16.0)
IgA: <0.15 (0.4–3.5)
IgM: 0.0 (0.5–3.0)
IgE: 440 (1.4–52.3)
Flow Cytometry

Gene
RAG2
Zygosity
Homozygous
Genomic
coordinate

SCID Omenn
syndrome

5 mo

Alive

Birth
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5

Combined/Cellular defects (n ¼ 7)
10.

4 mo/M

Recurrent diarrhea,
skin rash

1.5 mo

5

(continued)

5 mo/F

Consan
guinity

No

a

Special
Investigations
(Normal range)

Mutated
Gene

Final Diag
nosis

CD3: 150 (1800–3300)
CD4: 150 (900–2300)
CD8: 1 (700–1500)
CD56:108 (300–800)
CD19: 0 (700–1700)
HIV status: not checked

c.1247G > T
Amino acid
change
p.Trp416Leu

Immuno
globulins
IgG:0.66
(1.9–7.9)
IgA: <0.15
(0.01–0.59)
IgM: not done
IgE: 18 (1.4–52.3)
Flow Cytometry
CD3: 428 (2800–3500)
CD4: 283 (1700–2400)
CD8: 122 (800–1100)
CD56: not done
CD19: 25(1000–1700)
HIV serology: Negative

Gene
RAG1
Zygosity
Homozygous
Genomic
coordinate
Chr 11:
36597688_
A>
T ¼ c. 2834
A>T
Amino acid
change
p.H945L
SIFT (0.01);
Polyphen
(0.969).

SCID

Age at
onset of
sym
ptom

Age at
diag
nosis

3 mo

6mo

Recurrent
pneumonia,
diarrhea, otitis
media, skin
rash

Yes

Recurrent diarrhea,
oral thrush

Yes

No

Immunoglobulins
Ig G: 0.83 (not available)
IgA: 0.17 (not available)
IgM: 0.23 (not available)
IgE: not done
Flow cytometry
CD3: 32 (not available)
CD4: 6 (not available)
CD8: 23 (not available)
CD19: 397 (not available)
HIV serology: Negative

Gene
JAK3
Amino acid
change
p.P402L.
SIFT (0).
Polyphen
(0.85)

SCID

8 mo

1 yr 2 mo

Out
come

Died due to
ARDS and
PCP
pneumonia
(1 month
before
establishing
diagnosis)

b
b

Died due to
ARDS
(2 months
before
establishing
diagnosis)

12.

1 yr/F

13

2.5 yr/M

Oral thrush, skin rash,
Food allergy, anemia,
thrombocytopenia

Yes

No

Immunoglobulins
Ig G:19.4 (not available)
Ig A: 2.99(not available)
Ig M: 0.76(not available)
Ig E: >5000(not available)
Flow Cytometry
CD3: 1126(not available)
CD4: 285(not available)
CD8: 675(not available)
CD19: 75(not available)
CD56: 299(not available)
HIV status: not checked

Gene
WAS
Zygosity
Hemizygous
Genomic
coordinate
ChrX:
48543941
(Deletion of C)
Arg94fs
(Frameshift
deletion)

WAS

9 mo

3 yr 1 mo

Died due to
sepsis
(5 months
before
establishing
diagnosis)

14.

9 mo/F

Recurrent diarrhea,
pneumonia, oral and
perianal candidiasis

Yes

No

Immunoglobulins
IgG: 4.6 (6.5–16)
IgA: <0.33 (0.4–3.5)
IgM: 0.21 (0.5–3.0)
Ig E: 1.23 (1.4–52.3)
Flow cytometry

Gene
ZBTB24
Zygosity
Homozygous
Genomic
coordinate

ICF 2

4 mo

1 yr 10 mo

Died due to
Plastic
bronchitis.
(2.5 months
after
diagnosis)

b
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11.

Clinical
Features

6

S.No

Age/
Sex

Sibling
Death
(Age/
Cause of
death)

Chr6:
109802832
c.396_
397delTA
¼ p.His132fs
(Frameshift
deletion)

15

6 yr/M

Recurrent diarrhea,
pneumonia, occulocutaneous albinism,
blond hairs, easy
bruisibility, oral thursh

Yes

No

Immunoglobulins
Ig G: 9.7 (6.5–16)
Ig A: 4.0 (0.4–3.5)
IgM: 0.28 (0.5–3.0)
IgE: 28 (0.5–393)
Flow cytometry
Not done
HIV status: not checked

No
pathogenic
variant found
(Diagnosed on
the basis of
clinical
ﬁndings and
family history
of similar
illness in his
ﬁrst cousin)

HermanskyPudlack syndrome

16.

16 y/F

Recurrent diarrhea,
pneumonia, occulocutaneous albinism,
blond hairs, easy
bruisibility, oral thrush,
epistaxis, otitis media

Yes

Yes (2.5 years old
brother due to
pneumonia & had
similar features
and complaints)

Immunoglobulins
Ig G:17.8 (6.5–16)
Ig A: 4.48 (0.4–3.5)
IgM: 0.45 (0.5–3.0)
IgE: 12.0 (1.9–170)
Flow cytometry
CD3:1330 (720–2320)
CD4: 592 (430–1010)
CD8: 687 (170–1050)
CD19:175 (100–430)
CD56: 48 (100–430)
HIV serology:Negative

Not done
(Diagnosed on
the basis of
clinical
ﬁndings and
family history
of similar
illness in her
ﬁrst cousin)

HermanskyPudlack syndrome

Birth

7 yr

Alive

1 yr

17 yr

Alive

Volume 13, No. 7, Month 2020

CD3: 4286 (1900–2900)
CD4: 2942 (1000–1800)
CD8: 824 (700–1200)
CD56: 331 (300–600)
CD19: 944 (600–1400)
HIV status: not checked

Humoral/Antibody defects (n ¼ 3)
17.

3 yr/M

Recurrent diarrhea
Recurrent abscesses

Yes

No

Immunoglobulins
IgG: <0.7 (5.7–17.1)
IgM: <0.08 (0.64–2.7)
IgA: <0.15 (0.47–2.5)
IgE: 51 (0.4–351.6)
Flow cytometry
CD3: 1444 (1500–2900)
CD4: 389 (1000–2100)
CD8: 1064 (700–1100)
CD19: 2 (500–1200)
CD56: 165 (300–600)
HIV serology: Negative

Gene
BTK
Loss of
coverage
frameshift
deletion
resulting in
exon18 ¼
c.1883delC ¼
p.T628fs

X-linked Agammaglobulinemia

2yr

4yr 9 mo

Died due to
sepsis
(4 months
before
establishing
diagnosis)

18.

8 yr/F

Recurrent diarrhea and
pneumonia

Yes

No

Immunoglobulins
IgG:1.11(7.3–15.1)
IgM: 0.14(0.55–2.1)
IgA: <0.15 (0.7–3.25)
IgE: <0.1 (0.5–393)
Flow cytometry
CD3: 3472(1300–2200)
CD4: 1513 (600–1100)
CD8: 1787(500–1000)
CD19: 49(300–500)
CD56:176(300–500)
HIV status: not checked

Gene
TCF3
Zygosity
Homozygous
Loss of
coverage
Total loss of
coverage of
exons 5–11.

Agamma
globulinemia

1 yr

8 yr 7 mo

Alive

(continued)

7

8

Clinical
Features

19.

1.9 yr/M

Recurrent pneumonia

Consan
guinity

a

Special
Investigations
(Normal range)

Mutated
Gene

Final Diag
nosis

Yes

Yes (5 years old
brother due to
measles)

Immunoglobulins:
IgG: 9.64 (6.5–16.0)
IgM: 0.6 (0.5–3.0)
IgA: 0.69 (0.4–3.5)
IgE: 3.37 (0.4–351.6)
Flow cytometry:
CD3:1653 (1500–2900)
CD4:1242 (1000–2100)
CD8: 427 (700–1100)
CD19: 12 (500–1200)
CD56: 132 (300–600)
HIV status: not checked

Gene
TTC37
Zygosity
Homozygous
Genomic
coordinates
(GRCh37/
hg19):
c.1864A > C
Amino acid
change
p.Thr622Pro
Polyphen:
0.89
SIFT: 0.41

Trichohe
patoenteric
syndrome (THES)

Yes

No

Complement Level
C3: 0.05 g/L(0.8–1.5)

Gene
C3
Zygosity
Homozygous
Genomic
coordinates
(GRCh37/
hg19): Chr19:
6711208 C >
A (50
Splicesite,
Exon 12)

C3 deﬁciency

Age at
onset of
sym
ptom

Age at
diag
nosis

Birth

1 yr 10 mo

Alive

5 yr

Alive

Out
come

Complement Deﬁciency (n ¼ 1)
20.

4.5 yr/M

Recurrent meningitis

1 yr

Table 1. (Continued) Clinical and Laboratory characteristics of patients with a conﬁrmed Primary immunodeﬁciency disorder. a. CD count unit: cells/mm3,Immunoglobulin unit: G/L, IgE unit: IU/ml,
NBT: Nitrotetrazolium blue test, DHR: Dihydrorhodamine. b. ARDS: Acute Respiratory Distress Syndrome, PCP: Pneumocystis carini c. Sample sent to Armed Forces of Institute of Pathology (AFIP), Rawalpindi to check
the CD markers for Leukocyte Adhesion Defect (LAD) on ﬂow cytometry
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S.No

Age/
Sex

Sibling
Death
(Age/
Cause of
death)

a

Special Investigations
(Normal range)

Suspected
diagnosis

Gene
Sequence
Result

Age at onset
of symptom

Age/Sex

1

10 mo/M

Recurrent
diarrhea

Immunoglobulins
IgG:<0.7 (1.9–7.9)
IgA:<0.15 (0.01–0.59)
IgM:<0.08 (0.09–2.1)
IgE:1.0 (1.4–52.3)
Flow cytometry
CD3:166(1800–3300)
CD4:132(900–2300)
CD8: 27 (700–1500)
CD19: 22(700–1700)
CD56: 530(300–800)
HIV serology: negative

TBþNKSCID

Birth
No Known
candidate gene
for PID
identiﬁed

2

2.5 yr/M

Work up was
done because
of family history
of SCID.

Immunoglobulins
Not done
Flow cytometry
CD3:503(1500–2900)
CD4: 451(1000–2100)
CD8: 68(700–1100)
CD19:12(500–1200)
CD56: not done
HIV status: not checked

TB-NK- SCID

No Known
candidate gene
for PID
identiﬁed

3

6 mo/M

Fever, leg
gangrene,
seizures

Immunoglobulins
IgG:10.7(6.5–16)
IgA: 0.31(0.4–3.5)
IgM:0.2(0.5–3)
IgE:12.4(1.4–52.3)
Flow Cytometry
CD3:1140(1800–3300)
CD4:735(900–2300)
CD8: 449(700–1500)
CD56: 49 (300–800)
CD19: 273(700–1700)
HIV serology: negative

SCID

4

13 yr/M

Recurrent
diarrhea and
joint swelling

Immunoglobulins
IgG: 1.11(5.7–17.1)
IgA: 0.41(0.47–2.5)
IgM: 0.05(0.64–2.7)
IgE: 2.85(1.9–170)
Flow Cytometry
CD3:1718(1100–2200)
CD4: 651(600–1600)

No

Age at
diagnosis

Outcome

10 mo.

Died due to
sepsis

10th day of life

1 yr 8 mo.

Died due to
sepsis

No Known
candidate gene
for PID
identiﬁed

1.5 mo.

4 mo.

Alive
No
recurrence of
infections in
follow up.
Less likely to
be a PID

No Known
candidate gene
for PID
identiﬁed

6 yr.

13 yr.

Alive

9
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Clinical
Features

S.No

Age/Sex

a

Special Investigations
(Normal range)

Suspected
diagnosis

Gene
Sequence
Result

Age at onset
of symptom

Age at
diagnosis

Outcome

CD8: 850(500–1200)
CD19: 454(200–600)
CD56: 83(300–600)
HIV status:not checked
Fever and
seizures

Immunoglobulins
IgG:13.54(6.5–16)
IgA: 0.19 (0.4–3.5)
IgM: 2.8(0.5–3)
IgE: not done
Flow Cytometry
CD3:1624(2800–3500)
CD4: 592(1700–2400)
CD8: 831(800–1100).
CD19: 425(1000–1700)
CD56: 913(300–800)
HIV status: not checked

No

No Known
candidate gene
for PID
identiﬁed

4.5 mo.

6 mo.

Alive

11 mo/M

Recurrent
diarrhea and
pneumonia

Immunoglobulins
IgG:4.96((6.5–16))
IgM:0.09(0.5–3)
IgA: 0.16(0.4–3.5)
IgE:1.0(1.4–52.3)
Flow Cytometry
CD3: 244(1800–3300)
CD4: 105(900–2300)
CD8: 146(700–1500)
CD19:1.0(700–1700)
CD56: 89(300–800)
HIV status: Negative

SCID

No Known
candidate gene
for PID
identiﬁed

4 mo.

11 mo.

Alive
No
recurrence of
infections in
follow up.
Less likely to
be a PID

5.5 mo/M

Recurrent
pneumonia,
skin rash and
hyperglycemia

Immunoglobulins
IgG:0.26(6.5–16)
IgA: 0.09(0.4–3.5)
IgM:0.12(0.5–3)
IgE:5.96 (1.4–52.3)
Flow cytometry
CD3: 2244(1800–3300)
CD4: 879 (900–2300)
CD8: 1167(700–1500)
CD56:196 (300–800)
CD19: 21 (700–1700)
HIV status: not checked

Early onset
diabetes and
Agamma
globulinemia
STAT3 GOF?
LRBA?

No Known
candidate gene
for PID
identiﬁed

2 mo.

5 mo.

Alive
Recurrent
otitis media,
eczematous
skin rash and
failure to
thrive

5

8 mo/F

6

7

Table 2. Clinical and laboratory characteristics of suspected primary immunodeﬁciency patients with No known gene mutation for PID. a. CD count unit: cells/mm3,Immunoglobulin unit: G/L, IgE unit:
IU/ml
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Fig. 1 Study ﬂow showing distribution of study subjects

crucial in aiding and establishing the diagnosis of
suspected PIDs in these countries.9
Patients with PIDs are often diagnosed based on
a clinical history of recurrent infections due to
atypical or less virulent pathogens.16 However,
they can also present with non-infectious manifestations, such as autoimmune disease, or albinism.17 Verma et al published a case series of 27
PID cases in whom recurrent pneumonia and
recurrent diarrhea were the most common
presentations. In our case series, recurrent
diarrhea was the most common clinical
presentation followed by recurrent pneumonia,
oral thrush, skin rash, and abscesses.18
Live vaccines (eg, BCG, OPV) should not be
administered to children with PIDs due to the risk
of developing mycobacterial disease with the bacillus CalmetteGuérin (BCG) vaccine or Vaccine
Derived Poliovirus (VDP) with the oral polio virus
vaccine (OPV).19 Shahmohammadi S et al
reviewed 17 cases of disseminated BCG infection
in Iran from 2005 to 2010 and observed that 10
(59%) out of the 17 cases had impaired immunity
due to an incompetent immune system.20 In
Pakistan, these vaccines (BCG and OPV) are a
part of the national immunization programme;
hence, they are administered routinely, much
earlier before a diagnosis of immunodeﬁciency
can be suspected or established in children. In
our case series, almost all cases were vaccinated
with the BCG and OPV at birth; so far, none of

them have developed any sign of disease due to
the vaccination (VDP or Tuberculosis). Although
this report is based on a limited number of cases,
it does raise the need for a newborn screening
program in the long term, so that children
suspected of having a PID do not receive a live
vaccine at birth.
Early recognition and prompt diagnosis of PIDs
help in preventing signiﬁcant disease related
morbidity and mortality. A clinical history and
physical examination together with supportive
laboratory investigations can provide clues about
an underlying PID. Nevertheless, molecular testing
plays an essential role in not only conﬁrming the
diagnosis but also in identifying the exact nature of
the defect. It also assists in patient care as it allows
for prognostic counseling.21
Varying degree of support for diagnosing PIDs
is available from different institutions and philanthropic foundations such as the (International
Union of Immunological Sciences (IUIS), European
Society for Immunodeﬁciencies (ESID), Immune
Deﬁciency Foundation (IDF), and Jeffrey Modell
Foundation JMF). In most LMICs, diagnostic and
therapeutic services are sparse and/or inaccessible. Armed Forces Institute of Pathology (AFIP) in
Rawalpindi, Pakistan is a center where limited immune diagnostics are available but molecular
techniques are still lacking. Furthermore, this is the
only center where some form of diagnostics is
available for PIDs. For a country with a population

12

Qureshi et al. World Allergy Organization Journal (2020) 13:100133
http://doi.org/10.1016/j.waojou.2020.100133

of 200 million and a birth rate of 29.8 births per
1,000 people, a single facility is not enough to
meet the demands.

Derived Poliovirus; BMT: Bone Marrow Transplant; AFIP:
Armed Forces Institute of Pathology

To our knowledge, this is the ﬁrst report of PID
cases from Pakistan conﬁrmed with molecular
diagnosis. The cases reported here only reﬂect
cases referred to a large tertiary care center and
represent only the tip of the iceberg.
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As a next step, we plan to set up a national
registry to bring together individual efforts so that
medical care for affected individuals can be
improved. Having a national registry will facilitate
exchange of experience in the diagnosis and
management of PIDs with international registries
and will help push policies for support of children
with an identiﬁed PID. We plan to work towards
achieving philanthropic support for IVIG/SCIG or
bone marrow transplant (BMT) for the treatment of
diagnosed patients. Hopefully, these collective efforts will help with early identiﬁcation of PIDs, aid
in tracking and establishing epidemiological data
of PIDs in Pakistan, and help decrease the mortality
of patients in developing countries around the
world.
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CONCLUSION
PIDs are not uncommon in Pakistan; their diagnosis may be missed or delayed due to the overlapping of clinical features of PIDs with other
diseases and a lack of diagnostic facilities. There is
a need to increase testing capacity for early
recognition, diagnosis and management of PIDs to
decrease morbidity and mortality. There is also a
need to establish a national registry for estimating
the true burden of PIDs in the country to aid in
policy recommendations.
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